Full Year 2023 Life Healthcare Group Holdings Ltd Earnings Call Transcript
In the context of our overall results, we'll start with a strong underlying performance of our businesses. In South Africa, revenue grew by a shade over 10%, normalized EBITDA by 6.6% with paid patient days rising by nearly 10% during the course of the year. Life Molecular Imaging had a strong performance with revenue growing by 18.2%. Off the back of the news, the PET CT is now being reimbursed in the U.S. for Alzheimer's disease care pathways and Neuraceq has also received approval to be used in China.
The Alliance Medical Group, which we will discuss in more detail later on as the discontinued operation that we sold saw a growth in revenue in excess of 10%. We now -- we have reported that we have sold the business for GBP 910 million, the shareholder vote to approve the transaction will be on the 8th of December of this year, and we expect to close out all the conditions precedent by the beginning of quarter 2 of 2024.
Overall, the group's revenue is up 10%, normalized
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |